Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
- Analyst Ratings
Upturn AI SWOT - About
ARAY 
Accuray Incorporated (ARAY)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
03/27/2025: ARAY (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
AI Based Fundamental Rating
Below Average Performance
These Stocks/ETFs, based on Upturn Advisory, often underperform the market, warranting careful consideration before investing.
Analysis of Past Performance
Type Stock | Historic Profit -67.92% | Avg. Invested days 26 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 03/27/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 187.15M USD | Price to earnings Ratio - | 1Y Target Price 6.12 |
Price to earnings Ratio - | 1Y Target Price 6.12 | ||
Volume (30-day avg) 525615 | Beta 1.46 | 52 Weeks Range 1.40 - 2.95 | Updated Date 03/30/2025 |
52 Weeks Range 1.40 - 2.95 | Updated Date 03/30/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -0.04 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Revenue by Geography
Geography revenue - Year on Year
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin -0.96% | Operating Margin (TTM) 3.73% |
Management Effectiveness
Return on Assets (TTM) 0.97% | Return on Equity (TTM) -9.15% |
Valuation
Trailing PE - | Forward PE 16.56 | Enterprise Value 338057550 | Price to Sales(TTM) 0.41 |
Enterprise Value 338057550 | Price to Sales(TTM) 0.41 | ||
Enterprise Value to Revenue 0.75 | Enterprise Value to EBITDA 21.72 | Shares Outstanding 102831000 | Shares Floating 99492643 |
Shares Outstanding 102831000 | Shares Floating 99492643 | ||
Percent Insiders 2.53 | Percent Institutions 60.86 |
Analyst Ratings
Rating 4.75 | Target Price 6.12 | Buy 1 | Strong Buy 3 |
Buy 1 | Strong Buy 3 | ||
Hold - | Sell - | Strong Sell - | |
Strong Sell - |
Upturn AI SWOT
Accuray Incorporated
Company Overview
History and Background
Accuray Incorporated was founded in 1990 and is headquartered in Sunnyvale, California. It is a radiation oncology company that develops, manufactures, and sells radiotherapy systems for cancer treatment. It has evolved from a radiosurgery-focused company to one providing comprehensive radiation therapy solutions.
Core Business Areas
- Radiation Therapy Systems: Develops and sells the CyberKnife and TomoTherapy platforms used for precise radiation delivery to tumors while minimizing damage to surrounding healthy tissue.
- Service and Support: Provides service, maintenance, and training related to its installed base of radiotherapy systems.
- Software Solutions: Offers software for treatment planning, dose management, and data analysis to optimize treatment workflows.
Leadership and Structure
Suzanne Winter is the President and CEO. The company is structured with functional departments including sales, marketing, R&D, operations, and finance.
Top Products and Market Share
Key Offerings
- CyberKnife Robotic Radiosurgery System: A robotic radiosurgery system used for treating tumors anywhere in the body with sub-millimeter accuracy. It competes with Varian's Edge system and Elekta's Gamma Knife. Market share information is difficult to obtain precisely but estimates place Accuray with significant market share, though lower than leaders Varian and Elekta.
- TomoTherapy Platform: A radiation therapy system that integrates CT imaging with radiation delivery, allowing for precise and adaptive treatment planning. This platform competes with Varian's TrueBeam and Elekta's Unity systems. Similar to CyberKnife, precise market share data is not readily available, but Accuray holds a relevant portion of the market.
Market Dynamics
Industry Overview
The radiation oncology market is driven by the increasing prevalence of cancer, technological advancements in radiotherapy, and an aging global population. It's a competitive market with high barriers to entry due to regulatory requirements and complex technologies.
Positioning
Accuray is positioned as an innovator in precision radiation therapy, focusing on advanced technologies like robotic radiosurgery and image-guided radiation therapy. Their competitive advantage lies in the unique capabilities of their CyberKnife and TomoTherapy platforms.
Total Addressable Market (TAM)
The global radiation oncology market is estimated to reach upwards of $10 billion by 2028. Accuray is positioned to capture a portion of this TAM through its innovative technologies, though facing stiff competition from larger players.
Upturn SWOT Analysis
Strengths
- Innovative technology (CyberKnife, TomoTherapy)
- Precise and accurate radiation delivery
- Strong brand reputation in radiosurgery
- Established global installed base
Weaknesses
- Smaller market share compared to Varian and Elekta
- Financial performance can be volatile
- Reliance on capital equipment sales
- High service costs
Opportunities
- Expanding into emerging markets
- Developing new applications for existing technologies
- Strategic partnerships and collaborations
- Growing demand for personalized cancer treatment
Threats
- Intense competition from larger players (Varian, Elekta)
- Technological advancements by competitors
- Reimbursement pressures from healthcare providers
- Economic downturns affecting capital equipment spending
Competitors and Market Share
Key Competitors
- VAR
- EKTA-B.ST
Competitive Landscape
Accuray faces significant competition from larger, more established players like Varian and Elekta. Accuray differentiates itself through its unique technologies, while Varian and Elekta have broader product portfolios and larger installed bases.
Major Acquisitions
Growth Trajectory and Initiatives
Historical Growth: Accuray's historical growth has been moderate, with periods of rapid growth followed by periods of slower growth due to market conditions and competition.
Future Projections: Future growth projections depend on factors such as technological innovation, market expansion, and competitive landscape. Analyst estimates are publicly available from various financial sources.
Recent Initiatives: Recent initiatives include new product launches, strategic partnerships, and expansion into emerging markets.
Summary
Accuray holds a notable position in the radiation therapy market with its innovative CyberKnife and TomoTherapy systems, offering unique capabilities for precise cancer treatment. The company faces stiff competition from larger players and needs to focus on expanding market share and improving financial performance. Successful execution of strategic initiatives, such as expanding into emerging markets and developing new applications for its technologies, will be crucial for its future growth. The market for radiation oncology is growing, giving Accuray the potential for growth if they can differentiate themselves from larger companies.
Similar Companies
- VAR
- EKTA-B.ST
- MRK
Sources and Disclaimers
Data Sources:
- Accuray Investor Relations
- Industry Reports
- Financial News Outlets
- Competitor SEC Filings
- Analyst Reports
Disclaimers:
The data provided is for informational purposes only and should not be considered financial advice. Market share data is estimated and may vary. Investment decisions should be based on thorough research and consultation with a qualified financial advisor.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Accuray Incorporated
Exchange NASDAQ | Headquaters Madison, WI, United States | ||
IPO Launch date 2007-02-08 | President, CEO & Director Ms. Suzanne Winter M.B.A. | ||
Sector Healthcare | Industry Medical Devices | Full time employees 987 | Website https://www.accuray.com |
Full time employees 987 | Website https://www.accuray.com | ||
Accuray Incorporated designs, develops, manufactures, and sells radiosurgery and radiation therapy systems for the treatment of tumors in the United States, Canada, Latin America, Asia, Australia, New Zealand, Europe, the Middle East, India, Africa, Japan, and China. It offers the CyberKnife platform, a robotic stereotactic radiosurgery and stereotactic body radiation therapy system used for the treatment of primary and metastatic tumors outside the brain, including tumors on or near the spine and in the breast, kidney, liver, lung, pancreas, and prostate. The company also provides the TomoTherapy platform, including the Radixact System, which allows for integrated radiation treatment planning, delivery, and data management, enabling clinicians to deliver ultra-precise treatments to approximately 50 patients per day; iDMS data management system, a fully integrated treatment planning and data management systems; and Accuray precision treatment planning system, a treatment planning and data management systems. In addition, it offers post-contract customer support, installation, training, and other professional services. The company primarily markets its products directly to customers, including hospitals and stand-alone treatment facilities through its sales organization, as well as to customers through sales agents and group purchasing organizations in the United States; and to customers directly and through distributors and sales agents internationally. Accuray Incorporated was incorporated in 1990 and is headquartered in Madison, Wisconsin.
Upturn is now on iOS and Android!
Experience Upturn on your mobile. Install it now!
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.